{"id":200623,"date":"2024-12-02T11:27:38","date_gmt":"2024-12-02T17:27:38","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/12\/car-t-cells-armed-with-il-15-show-promise-in-treating-solid-cancers"},"modified":"2024-12-02T11:27:38","modified_gmt":"2024-12-02T17:27:38","slug":"car-t-cells-armed-with-il-15-show-promise-in-treating-solid-cancers","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/12\/car-t-cells-armed-with-il-15-show-promise-in-treating-solid-cancers","title":{"rendered":"CAR T cells armed with IL-15 show promise in treating solid cancers"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/car-t-cells-armed-with-il-15-show-promise-in-treating-solid-cancers.jpg\"><\/a><\/p>\n<p>A new study published in the journal <a href=\"https:\/\/www.nature.com\/articles\/s41586-024-08261-8\"><em>Nature<\/em><\/a> reports results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3 (GPC3). Researchers at Baylor College of Medicine and Texas Children\u2019s Cancer Center led the study, which tested chimeric antigen receptor (CAR) T cells enhanced with the protein interleukin-15 (IL-15).<\/p>\n<p>CAR T cells have shown limited efficacy in patients with solid cancers, despite dramatic success in some hematologic malignancies. Preclinical studies showed that the addition of IL-15, which helps T cells survive and multiply, could improve the performance of CAR T cell-based immunotherapies.<\/p>\n<p>In these trials, researchers tested GPC3-specific CAR T cells co-expressing IL-15 in adults with hepatocellular carcinoma (HCC) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT02905188\">NCT02905188<\/a>) and children with GPC3 expressing solid tumors, including HCC (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT02932956\">NCT02932956<\/a>). The first patient cohorts received GPC3-CAR T cells alone. The GPC3-CAR T cells were found to be safe, with peak cell expansion at two-weeks post-infusion; however, no objective antitumor responses were observed.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new study published in the journal Nature reports results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3 (GPC3). Researchers at Baylor College of Medicine and Texas Children\u2019s Cancer Center led the study, which tested chimeric antigen receptor (CAR) T cells enhanced with the protein interleukin-15 [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-200623","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/200623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=200623"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/200623\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=200623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=200623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=200623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}